D
grade
Nisotirostide (LY3457263), a novel NPY2 receptor agonist for type 2 diabetes and obesity: From discovery to clinical proof of concept.
Nisotirostide · Molecular metabolism · 2026 · RCTHigh-impact journal
Nisotirostide showed a potential for weight reduction when combined with dulaglutide, but the monotherapy results were not statistically significant.
Nisotirostide reduced mean body weight by 0.75 kg versus placebo (ns); when added to dulaglutide, up to 2.58 kg reduction was observed versus dulaglutide alone (p<0.05).